But Canadian drug suppliers have said they won't participate, and the Biden administration itself has argued in court filings that the
"Rather than rehashing old, flawed ideas that expose Americans to unapproved and potentially dangerous medicines, the next Congress should consider policies that support medical innovation and ensure Americans have access to the best and safest treatments available,” said Gabby Migliara, a spokesperson for PhRMA, the big Washington industry trade group.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: